Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.44 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329204 | 0.90 | RET (0.50) | RETTLK2GSK3BFLT3FLT4 | |
| SCHEMBL6330789 | 0.89 | RET (0.47) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6332669 | 0.89 | RET (0.47) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6337189 | 0.87 | RET (0.44) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6328899 | 0.86 | RET (0.48) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6337029 | 0.85 | RET (0.43) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6336551 | 0.85 | RET (0.43) | RETCHEK1TLK2GSK3BFLT3 | |
| SCHEMBL6329102 | 0.85 | RET (0.45) | RETTLK2GSK3BFLT3FLT4 | |
| SCHEMBL6335938 | 0.85 | RET (0.46) | RETTLK2GSK3BFLT3FLT4 | |
| SCHEMBL6331496 | 0.85 | ACHE (0.43) | RETTLK2FLT3BRD4PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | RET 154/4885CHEK1 145/4885TLK2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.